Eterna (ERNA) Therapeutics announced the addition of Jerome Zeldis, M.D., Ph.D., and Blythe Sather, Ph.D., to the company’s scientific advisory board. With their deep insight and experience in cell therapy, Dr. Zeldis and Dr. Blythe will play a role in advancing ERNA-101 in solid tumors and ERNA-102 in autoimmune diseases through their preclinical studies.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.